Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?

Endocr Connect. 2023 Sep 27;12(11):e230257. doi: 10.1530/EC-23-0257. Print 2023 Nov 1.

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.

Keywords: dipeptidyl peptidase IV; glucagon-like peptide 1 receptor agonist; incretin system; medullary thyroid cancer; papillary thyroid cancer.

Publication types

  • Review